Narendranath Epperla, MBBS, MS

home / authors / narendranath-epperla-mbbs-ms

Articles

Narendranath Epperla, MD, MS, a hematologist specializing in the treatment of Hodgkin and non-Hodgkin lymphomas at The Ohio State University Comprehensive Cancer Center—James,

Dr. Epperla on the Implications of an FDA Approval for Ublituximab/Umbralisib in CLL

June 12th 2021

Narendranath Epperla, MD, MS, discusses the implications of a potential FDA approval for the combination of ublituximab and umbralisib for patients with chronic lymphocytic leukemia.

Dr. Epperla on Future Research Efforts in MCL

Narendranath Epperla, MBBS, MS

June 12th 2021

Narendranath Epperla, MD, MS, discusses future research efforts in mantle cell lymphoma.

Dr. Epperla on FDA Approval of Frontline Obinutuzumab in Follicular Lymphoma

Narendranath Epperla, MBBS, MS

November 16th 2017

Narendranath Epperla, MBBS, MS, hematologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of frontline obinutuzumab (Gazyva) for the treatment of patients with follicular lymphoma.

Dr. Epperla on CAR T-Cell Therapy in MCL

Narendranath Epperla, MBBS, MS

November 15th 2017

Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).

Dr. Epperla on Treatment Following Ibrutinib in MCL

Narendranath Epperla, MBBS, MS

November 1st 2017

Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the next steps for patients with mantle cell lymphoma (MCL) who fail ibrutinib (Imbruvica).

Dr. Epperla Discusses the Current Treatment of MCL

Narendranath Epperla, MBBS, MS

October 18th 2017

Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the current treatment landscape of patients with mantle cell lymphoma.